tiprankstipranks
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders StocksMarket MoversTipRanks 50 IndexAI StocksLargest Companies by Market Cap
ETFs
Top ETFs by UpsideTop ETFs by Smart ScoreTop Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Research Tools
Trending StocksCompare StocksCompare ETFsTrump Dashboard
New
Daily Feeds
Daily Analyst RatingsDaily Insider Trading Tracker
Calendars
Earnings CalendarDividend CalendarEconomic CalendarIPO CalendarStock SplitsStock BuybacksMarket Holidays
Calculators
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Economic Indicators
Inflation RateUnemployment Rate
Class Actions
Stock ScreenerETF Screener
Popular
Penny Stock ScreenerTechnical Analysis Screener
Dividend CenterBest Dividend Stocks
Popular
Best High Yield Dividend StocksDividend AristocratsDividend Stock Comparison
New
Dividend CalculatorDividend Returns ComparisonDividend Calendar
My ExpertsTop AnalystsTop Financial BloggersTop-Performing Corporate InsidersTop Hedge Fund ManagersTop Research FirmsTop Individual Investors
Trending News
More News >
Education
Personal FinanceHow To Use TipRanksTipRanks LabsGlossaryFAQs
About Us
About TipRanksContact UsCareersReviewsMobile APP
Working with TipRanks
Enterprise SolutionsAdvertise with UsTop Online BrokersBecome an AffiliateTipRanks News Wire
Follow Us
TOOLS
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Market Movers
Compare stocks
Compare ETFs
Notification Center
News
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders Stocks
Compare Stocks
Compare ETFs
Trending Stocks
Daily Analyst Ratings
Daily Insiders Trades
Dividend Stocks
ETF Center
Top Gainers/losers/active ETFs
Trump Dashboard
New
Dividend Calculator
Options Profit Calculator
Dollar Cost Averaging
Compound Interest Calculator
Mortgage Calculator
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
Market Holidays
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Top Gainers
Top Losers
Most Active
Premarket
After-hours
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Real Estate
Top Online Brokers
Enterprise Solutions
Plans & Pricing
Education
How To Use TipRanks
TipRanks Labs
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us
STOCKS
SPY
QQQ
AAPL
NVDA
TSLA
AMZN
BABA
Advertisement
Advertisement

STOK Stock Latest News

Promising Potential of Stoke Therapeutics’ Zorevunersen as a Disease-Modifying Therapy for Dravet Syndrome: Analyst Recommends Buy Rating
RatingsPromising Potential of Stoke Therapeutics’ Zorevunersen as a Disease-Modifying Therapy for Dravet Syndrome: Analyst Recommends Buy Rating
8d ago
STOK
Stoke Therapeutics price target raised to $35 from $22 at Needham
PremiumThe Fly
Stoke Therapeutics price target raised to $35 from $22 at Needham
8d ago
STOK
Biogen, Stoke Therapeutics present follow-up analyses from zorevunersen studies
PremiumThe Fly
Biogen, Stoke Therapeutics present follow-up analyses from zorevunersen studies
9d ago
BIIB
STOK
Stoke, Biogen presents new data from OLE studies of zorevunersen
PremiumThe Fly
Stoke, Biogen presents new data from OLE studies of zorevunersen
9d ago
BIIB
STOK
Stoke Therapeutics Appoints Ian F. Smith as CEO
PremiumCompany Announcements
Stoke Therapeutics Appoints Ian F. Smith as CEO
12d ago
8K
STOK
Stoke Therapeutics appoints Ian Smith as CEO
PremiumThe FlyStoke Therapeutics appoints Ian Smith as CEO
12d ago
STOK
Stoke, Biogen announce data from open-label extension studies of zorevunersen
Premium
The Fly
Stoke, Biogen announce data from open-label extension studies of zorevunersen
2M ago
BIIB
STOK
Biogen, Stoke presents data from Phase 1/2a, OLE studies of zorevunersen
Premium
The Fly
Biogen, Stoke presents data from Phase 1/2a, OLE studies of zorevunersen
2M ago
BIIB
STOK
Promising Potential of Stoke Therapeutics: Buy Rating Supported by Positive Zorevunersen Data and Strategic Advancements
PremiumRatings
Promising Potential of Stoke Therapeutics: Buy Rating Supported by Positive Zorevunersen Data and Strategic Advancements
2M ago
STOK
Biogen, Stoke Therapeutics present data from studies of zorevunersen
PremiumThe Fly
Biogen, Stoke Therapeutics present data from studies of zorevunersen
2M ago
BIIB
STOK
Stoke Therapeutics price target lowered to $28 from $29 at BTIG
PremiumThe Fly
Stoke Therapeutics price target lowered to $28 from $29 at BTIG
2M ago
STOK
Stoke Therapeutics: Promising Outlook with Strong Financial Position and Advancing Clinical Trials Justifies Buy Rating
PremiumRatings
Stoke Therapeutics: Promising Outlook with Strong Financial Position and Advancing Clinical Trials Justifies Buy Rating
2M ago
STOK
Promising Developments in Stoke Therapeutics’ Clinical Trials Support Buy Rating
PremiumRatingsPromising Developments in Stoke Therapeutics’ Clinical Trials Support Buy Rating
2M ago
STOK
Positive Outlook for Stoke Therapeutics: Promising Clinical Data and Strong Financial Position
Premium
Ratings
Positive Outlook for Stoke Therapeutics: Promising Clinical Data and Strong Financial Position
2M ago
STOK
Stoke Therapeutics Advances RNA Medicine with Strong Q2 Results
Premium
Company Announcements
Stoke Therapeutics Advances RNA Medicine with Strong Q2 Results
2M ago
STOK
Stoke Therapeutics reports Q2 EPS (40c), consensus (54c)
PremiumThe Fly
Stoke Therapeutics reports Q2 EPS (40c), consensus (54c)
2M ago
STOK
Stoke Therapeutics, Biogen announce first patient dosed in EMPEROR study
PremiumThe Fly
Stoke Therapeutics, Biogen announce first patient dosed in EMPEROR study
2M ago
BIIB
STOK
Biogen, Stoke announce first patient dosed in Phase 3 EMPEROR study
PremiumThe Fly
Biogen, Stoke announce first patient dosed in Phase 3 EMPEROR study
2M ago
BIIB
STOK
STOK Earnings Report this Week: Is It a Buy, Ahead of Earnings?
PremiumPre-Earnings
STOK Earnings Report this Week: Is It a Buy, Ahead of Earnings?
2M ago
STOK
Stoke Therapeutics initiated with a Buy at Jefferies
PremiumThe FlyStoke Therapeutics initiated with a Buy at Jefferies
3M ago
STOK
Stoke Therapeutics’ EMPEROR Study: A New Hope for Dravet Syndrome
Premium
Company Announcements
Stoke Therapeutics’ EMPEROR Study: A New Hope for Dravet Syndrome
3M ago
STOK
Buy Rating for Stoke Therapeutics: Promising Dravet Syndrome Treatment Shows Significant Improvements
Premium
Ratings
Buy Rating for Stoke Therapeutics: Promising Dravet Syndrome Treatment Shows Significant Improvements
3M ago
STOK

Trending

Name
Price
Price Change
SPX
S&P 500
DJIA
Dow Jones
NDX
Nasdaq 100
More Trending Stocks >